PHS
ABBV icon

PFM Health Sciences’s AbbVie ABBV Stock Holding History

PFM Health Sciences’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,782
Closed -$7.57M – 73
2025
Q2 		$7.57M Sell
40,782
-290,959
-88% -$54.1M 0.64% 38
2025
Q1 		$69.5M Hold
331,741
– – 5.05% 2
2024
Q4 		$59M Sell
331,741
-72,120
-18% -$13.3M 3.65% 5
2024
Q3 		$79.8M Hold
403,861
– – 4.52% 4
2024
Q2 		$69.3M Hold
403,861
– – 3.43% 7
2024
Q1 		$73.5M Sell
403,861
-3,152
-0.8% -$543K 3.46% 4
2023
Q4 		$63.1M Sell
407,013
-94,179
-19% -$13.7M 3.78% 4
2023
Q3 		$74.7M Sell
501,192
-3,306
-0.7% -$485K 3.52% 3
2023
Q2 		$68M Buy
504,498
+215,595
+75% +$31.6M 2.64% 8
2023
Q1 		$46M Sell
288,903
-40,441
-12% -$6.18M 2.03% 14
2022
Q4 		$53.2M Buy
329,344
+12,181
+4% +$1.87M 1.91% 12
2022
Q3 		$42.6M Buy
317,163
+70,928
+29% +$10.2M 1.54% 26
2022
Q2 		$37.7M Buy
+246,235
New +$37.6M 1.44% 29
2022
Q1 		– Sell
-916,496
Closed -$124M – 69
2021
Q4 		$124M Hold
916,496
– – 4.23% 3
2021
Q3 		$98.9M Sell
916,496
-10,327
-1% -$1.18M 2.91% 6
2021
Q2 		$104M Hold
926,823
– – 3.27% 6
2021
Q1 		$100M Hold
926,823
– – 3.06% 6
2020
Q4 		$99.3M Buy
926,823
+425,073
+85% +$40.8M 3.49% 3
2020
Q3 		$43.9M Sell
501,750
-142,838
-22% -$13.4M 2.03% 13
2020
Q2 		$63.3M Sell
644,588
-79,586
-11% -$7.01M 3.28% 5
2020
Q1 		$55.2M Buy
724,174
+557,935
+336% +$47.5M 4.53% 2
2019
Q4 		$14.7M Buy
+166,239
New +$13.8M 0.7% 41
2017
Q2 		– Sell
-526,354
Closed -$34.3M – 91
2017
Q1 		$34.3M Sell
526,354
-645,013
-55% -$40.6M 0.86% 49
2016
Q4 		$73.4M Buy
1,171,367
+1,045,383
+830% +$63.8M 2.07% 17
2016
Q3 		$7.73M Sell
125,984
-953,642
-88% -$61.7M 0.23% 77
2016
Q2 		$66.1M Sell
1,079,626
-1,316,702
-55% -$80.2M 2% 15
2016
Q1 		$137M Buy
+2,396,328
New +$134M 4.22% 2

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PFM Health Sciences's ABBV Position: Q3 2025 in Review

PFM Health Sciences sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 40,782 shares — an estimated $7.57M sold.

PFM Health Sciences first reported a position in ABBV in Q1 2016 and held it in 27 quarters. The position peaked at $137M in Q1 2016. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • PFM Health Sciences reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
  • PFM Health Sciences sold 40,782 AbbVie shares in Q3 2025, an estimated $7.57M.
  • PFM Health Sciences first reported a position in AbbVie in Q1 2016 and held it in 27 quarters.
  • PFM Health Sciences's AbbVie position peaked at $137M in Q1 2016.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on PFM Health Sciences's 13F filing for Q3 2025, filed 14 Nov 2025.